![Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-5021600-150x150.jpg "Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37] 14")
Endothelial cannabinoid CB1 receptor deficiency reduces shear stress-induced arterial disease
#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians managing cardiovascular disease need to understand that CB1 receptor activation in blood vessels may contribute to atherosclerosis development, particularly in areas prone to abnormal blood flow patterns. This finding suggests that cannabis use could potentially worsen atherosclerotic plaque formation through endothelial CB1 signaling, which has direct implications for counseling patients with existing cardiovascular disease or risk factors. The research provides a mechanistic basis for reconsidering cannabis recommendations in patients with hypertension, coronary artery disease, or stroke risk.
This research demonstrates that cannabinoid CB1 receptors are present in human atherosclerotic plaques and are activated by the abnormal blood flow patterns that characterize high-risk arterial regions. When CB1 receptor function was experimentally reduced in endothelial cells, the researchers observed decreased arterial stiffening and reduced atherosclerotic plaque formation in response to pro-atherosclerotic flow conditions. These findings suggest that CB1 receptor signaling in blood vessel linings may contribute to vascular disease progression, potentially through mechanisms that promote endothelial dysfunction and plaque development. The results add to a growing body of evidence indicating that cannabis and cannabinoid effects on vascular biology are more complex than previously understood, with CB1 activation appearing to promote rather than protect against atherosclerosis in this context. For clinicians, this research highlights the need for caution when considering cannabis use in patients with cardiovascular risk factors or established atherosclerotic disease, as CB1 receptor activation may exacerbate vascular pathology despite any potential therapeutic benefits in other conditions. Patients with atherosclerosis or significant cardiovascular disease should discuss cannabis use with their physicians given the potential for CB1-mediated promotion of vascular disease.
“This is promising preclinical work showing CB1 receptor involvement in endothelial responses to shear stress, but we’re looking at mechanistic findings in controlled settings that need validation in human cardiovascular outcomes before we can draw clinical conclusions about cannabis use and atherosclerosis risk.”
💊 While preclinical evidence suggests that cannabinoid CB1 receptors on endothelial cells may contribute to atherosclerotic plaque formation under conditions of abnormal blood flow, translating these findings to clinical practice requires considerable caution. The study describes mechanistic associations in controlled experimental settings that may not fully capture the complex interplay of genetic, metabolic, and inflammatory factors driving atherosclerosis in patients, nor do they clarify whether CB1 expression is a primary driver or an epiphenomenon of vascular disease. Current cannabis use itself involves multiple cannabinoids and other compounds with varying pharmacology, and the net cardiovascular effects of smoked or ingested cannabis in human populations remain inconsistent across observational studies due to confounding by smoking exposure, underlying cardiovascular risk factors, and use patterns. Clinicians should avoid encouraging cannabis use as a cardiovascular protective strategy based on this mechanism alone, but may consider whether patients
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
